---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-007294"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:00:33.307942+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VYNE reports FY2022 net loss $23.2M; VYN201 Phase 1b in vitiligo dosing

## Summary
- GAAP net loss of $23.2M for FY2022 vs $73.3M in 2021; adjusted net loss $18.9M.
- Topline Phase 1b data for VYN201 (pan-BD BET inhibitor) in vitiligo expected mid-2023.
- Positive preliminary Phase 1a safety data for VYN201; three doses selected for Phase 1b.
- Regained Nasdaq minimum bid price compliance after 1-for-18 reverse stock split in Feb 2023.
- VYN202 option agreement extended to April 2023; IND-enabling studies planned.

## SEC filing metadata
- accession: 0001628280-23-007294
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000162828023007294/0001628280-23-007294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000162828023007294/mnlo-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-007294
- JSON: https://secwatch.observer/filing/0001628280-23-007294.json
- Plain text: https://secwatch.observer/filing/0001628280-23-007294.txt

## Key facts
- Earnings Releases
  VYNE Therapeutics Inc. reported financial results for year ended December 31, 2022.
  - Period: year ended December 31, 2022
  - Result: reported results
  source text: On March 9, 2023, VYNE Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000162828023007294/0001628280-23-007294-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.